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Abstract
We investigated the effect of Mycobacterium tuberculosis culture
supernatant added to sputum cultures collected during the ﬁrst
8 weeks of anti-tuberculosis treatment. With ongoing treatment
duration, time to culture positivity decreased signiﬁcantly in
supernatant-enriched cultures, possibly due to stimulation of
dormant or slowly metabolizing M. tuberculosis cells.
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Resuscitation-promoting factors (Rpf) are mycobacterial pro-
teins secreted by viable cells of Mycobacterium tuberculosis
stimulating (re)growth of dormant, non-replicating M. tubercu-
losis cells in vitro [1–3]. Recently, Mukamolova et al. have
demonstrated that sputum samples from untreated tubercu-
losis patients reveal a bacterial subpopulation that can be
cultured only by addition of Rpf [4]. During chemotherapy,
which reduces the viable M. tuberculosis population mainly by
acting on metabolically active cells, the dormant population is
expected to progressively increase in size relative to the
population that can still be recovered by conventional culture
[1,4,5]. It has not been studied whether the addition of Rpf to
sputum cultures collected during anti-tuberculosis treatment
alters the quantitative or qualitative culture yield. A readily
available method to detect all viable M. tuberculosis cells,
including the otherwise metabolically inactive cells that cannot
be grown by conventional culture methods, would greatly
enhance our ability to guide tuberculosis treatment in the clinic
and to validate novel regimens.
We used excess sputum from samples collected within
the ﬁrst 8 weeks of anti-tuberculosis treatment trials. Ethical
approval was granted and all participants provided written
informed consent. Sputa were transported at 4°C to a single
mycobacteriology laboratory (Department of Biomedical
Sciences, Stellenbosch University, Tygerberg, South Africa),
digested and decontaminated using a commercially available
system (NAC-PAC EA3, AlphaTec, Vancouver, WA, USA).
Puriﬁed Rpf are not commercially available but a medium
containing Rpf can be obtained from early stationary phase
culture supernatant (ESPSN) of M. tuberculosis [6,7]. To
produce ESPSN, Mycobacteria Growth Indicator Tubes
(MGITs; Becton Dickinson, Sparks, MD, USA; BD) were
inoculated with M. tuberculosis strain H37Rv (ATCC 27294),
supplemented with 800 lL OADC (oleic acid-albumin-dex-
trose-catalase; BD) and PANTA (polymyxin B, amphotericin
B, nalidixic acid, trimethoprim and azlocillin; BD), and
subsequently incubated for 28 days at 37°C [7]. After this,
tubes were centrifuged (3000 g, 4°C, 20 min), and the
ESPSN was harvested, ﬁltered (0.22 lm pore size, Merck
Millipore, Billerica, MA, USA), tested for bacterial contam-
ination and frozen at 80°C until use. For each patient
sample, four MGITs were prepared. Two control MGITs
contained 8 mL of original medium. From the two other
MGITs, 4 mL was removed and 4 mL of Rpf-containing
ESPSN was added instead. All four tubes were inoculated
with 500 lL of processed sputum supplemented with
OADC/PANTA and incubated at 37°C in a BD BACTEC
MGIT 960 System. One control and one ESPSN tube were
harvested after 7 days for colony forming unit (CFU)
counting. Serial dilutions of 100 to 105 in sterile saline
containing 0.01% Tween were spread on Middlebrook 7H11
agar plates supplemented with OADC and Selectatab
(polymyxin B, amphotericin B, ticarcillin, trimethoprim; Mast,
Bootle, Merseyside, UK). CFUs were counted after 21 days
and reported as CFU/mL (SD). The two remaining MGITs
were incubated until ﬂagged positive and time to positivity
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(TTP) recorded in hours (SD). Negative and contaminated
cultures were excluded from analysis. CFU and TTP were
compared using Mann–Whitney U and Kruskal–Wallis tests
and correlations were calculated using Spearman’s rank sum
test; a p-value of <0.05 was considered signiﬁcant.
We collected n = 79 sputum samples from 15 patients with
newly diagnosed pulmonary tuberculosis (n = 19, pretreat-
ment samples; n = 27, day 1–7; n = 13, day 14; n = 2, day 21;
n = 6, day 28; n = 2, day 35; n = 4, day 42; n = 3, day 49; and
n = 3, day 56 of treatment). In total, n = 316 MGITs were
prepared (n = 79 controls and n = 79 ESPSN-containing tubes
for TTP and logCFU, respectively), resulting in 2 9 79 pairs.
In the TTP series, four samples showed bacterial contamina-
tion (all incubated with ESPSN), 11 pairs showed no growth.
In the CFU series, six pairs were contaminated (n = 12) and
13 pairs showed no growth (n = 26). In total, n = 64 and
n = 58 pairs were included for TTP and CFU analysis,
respectively.
Overall, ESPSN medium non-signiﬁcantly accelerated TTP
by 18.2  128 h and decreased plate counts by 0.54  0.35
logCFU (p = 0.572 and p = 0.591, respectively; Mann–Whit-
ney U-test; Table 1). However, when we categorized the
differences in TTP between pairs (DTTP = TTP control – TTP
ESPSN) into groups of length of treatment for ≤7 days and
≥14 days, there was a signiﬁcant trend towards increased
DTTP with longer time on treatment (7.2  32 h vs.
37.8  212 h, p = 0.01; Kruskal–Wallis test, Table 1). The
increase in DTTP between ESPSN-containing and control
samples was positively correlated with the duration of
anti-tuberculosis treatment (p = 0.006, R = 0.339). Such a
trend was not observed for logCFU (p = 0.206; R = 0.169),
and no difference was found when DlogCFU was grouped for
length of treatment (Table 1).
The key observation in this study is the treatment
duration-dependent trend of ESPSN-containing sputum cul-
tures to display shorter TTPs but not increased CFUs. As
sputum samples collected during anti-tuberculosis treatment
contain decreasing numbers of viable M. tuberculosis with an
increasing proportion of dormant or metabolically inactive
cells [1,4,5], our data indicate that ESPSN either increases the
metabolic activity of M. tuberculosis not growing on solid agar,
or it resuscitates metabolically inactive M. tuberculosis unable
to grow on solid agar, or both. In other words, we cannot
conclusively tell if we have produced an acceleration model
and/or a resuscitation model.
Potential shortcomings include that the supernatant might
contain other factors that contribute to stimulation or
inhibition of growth or resuscitation of M. tuberculosis. Also,
ESPSN and control media were not entirely identical. Due to
the speciﬁc ﬂuorescence-quenching technology of the MGIT
system, a lower initial oxygen concentration of the partially
spent ESPSN medium could contribute to the accelerated
mean TTP of ESPSN samples. This would, however, not
explain the signiﬁcantly larger acceleration seen in samples
collected later in treatment. While both media types were
sufﬁciently enriched with nutrients, the ESPSN contained a
slightly higher concentration of antibiotics that were carried
over from the media preparation. This has been shown to
diminish growth of M. tuberculosis in liquid broth [8] and would
thus be inﬂuencing the results against the trend observed and
make our ﬁndings more robust.
This is the ﬁrst time ESPSN has been demonstrated to
inﬂuence growth of M. tuberculosis from clinical samples
collected during anti-tuberculosis treatment. To investigate
whether ESPSN could lead to new insights in true bacterial
loads at week 8 of treatment (culture conversion), this
biomarker has to be further evaluated and the focus should be
on samples collected in later phases of treatment. Also, efforts
should be made to provide a puriﬁed Rpf with a predictable
effect on M. tuberculosis.
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TABLE 1. Culture growth in normal and ESPSN-enriched media
Pairs, n TTP, h control DTTP, h to ESPSN Pairs, n logCFU/mL control DlogCFU/mL to ESPSN
All 64 286 (189) 18.2 (128) 58 3.94 (1.79) 0.54 (0.35)
Day 0–7 41 193 (73) 7.2 (32) 45 4.57 (1.40) 0.068 (0.37)
Day 14–56 23 472 (207) 37.8 (212) 13 1.77 (1.18) 0.007 (0.27)
p 0.01 0.851
Values are mean (SD). p: between samples collected at day 0–7 and day 14–56 of treatment (Kruskal–Wallis test). TTP, time to positivity; ESPSN, early stationary phase culture
supernatant; Day, days of anti-tuberculosis treatment received.
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